NCT04323865

Brief Summary

Need statement \- a new way to distinguish between a healthy small fetus and a small fetus suffering from deprivation of nutrition and oxygen to prevent unnecessary induction of preterm birth and improve neonatal outcome. Aim - to characterize fetal heart rate variability (fHRV) based on fetal ECG in the normal fetus and in the fetus suffering from growth retardation to evaluate its value and applicability as a supplementary tool in fetal surveillance. Aim of current study \- To evaluate the feasibility of NI-FECG from gestational week 20 and onwards and investigate if important factors as length and heart rate pattern affects repeatability of time domain and spectral analyses in fetuses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

February 20, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 27, 2020

Completed
Last Updated

November 23, 2020

Status Verified

February 1, 2020

Enrollment Period

1.7 years

First QC Date

February 20, 2020

Last Update Submit

November 20, 2020

Conditions

Outcome Measures

Primary Outcomes (5)

  • Standard deviation of normal to normal RR-interval (SDNN)

    Time domain analysis, measured in ms

    01.04.2020

  • Root mean square of successive RR-interval differences (RMSSD)

    Time domain analysis, measured in ms

    01.04.2020

  • Low frequency power (LF-power)

    Spectral analysis, measured in ms\^2

    01.04.2020

  • High frequency power (HF-power)

    Spectral analysis, measured in ms\^2

    01.04.2020

  • LF-power/HF-power

    Spectral analysis, ratio

    01.04.2020

Study Arms (1)

Study 2. Repeatability of FHRV

Diagnostic Test: fetal heart rate variability

Interventions

No direct intervention, as the study is observational.

Study 2. Repeatability of FHRV

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Danish. Healthy. Pregnant women. Expecting a healthy fetus.

You may qualify if:

  • Healthy singleton pregnancies

You may not qualify if:

  • Fetal malformations, multiple pregnancy, obstetric complications, maternal chronic disease and labor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arhus Universityhospital

Aarhus, Aarhus N, 8200, Denmark

Location

MeSH Terms

Conditions

Fetal Growth Retardation

Condition Hierarchy (Ancestors)

Fetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGrowth DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2020

First Posted

March 27, 2020

Study Start

June 1, 2018

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

November 23, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations